COMMUNICATION
News & Press Release
Total 122
-
82CNR Research, NeuroBiogen U.S. FDA Pre-IND Contract.
DATE : 2023-10-04
VIEW : 2734
-
81Neurobiogen U.S. FDA Phase 2 Pre-IND Application.
DATE : 2023-10-04
VIEW : 2769
-
80CNR Research Applies for New Obesity and Dementia Substances Neurobiogen U.S. FDA Pre-IND.
DATE : 2023-10-04
VIEW : 2627
-
79CNR Research, Neurobiogen U.S. FDA Pre-IND Contract.
DATE : 2023-10-04
VIEW : 2731
-
78CNR Research "Neurobiogen Obesity Treatment Applies for FDA Pre-IND".
DATE : 2023-10-04
VIEW : 2686
-
77CNR Research Signs U.S. Phase 2 Pre-IND Agreement With Neurobiogen.
DATE : 2023-10-04
VIEW : 2731
-
76CNR Research Signs U.S. Phase 2 Pre-IND Promotion With NeuroBiogen.
DATE : 2023-10-04
VIEW : 2684
-
75"You lose weight even if you eat the same amount".Domestic and foreign stock markets fluctuate due t
DATE : 2023-09-11
VIEW : 2876
-
74Obesity, diabetes medicine that can't be sold because it's not there...Pharmaceutical Bio to Develop
DATE : 2023-09-08
VIEW : 2695
-
73Neurobiogen "Development of an innovative obesity drug that loses weight by eating without yo-yo and
DATE : 2023-09-07
VIEW : 2734
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved